--- title: "BioAge Labs (BIOA) news: class action, IPO and offering" url: "https://aibio.space/companies/bioage-labs/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BIOA class action, IPO and offering news: BioAge faces Ninth Circuit appeal of dismissed IPO securities class action. BioAge Labs, Inc." --- BIOA BioAge Labs, Inc. NASDAQ · United States # BioAge Labs (BIOA) news BIOA class action, IPO and offering news Legal · 2026-08-05 ## [BioAge faces Ninth Circuit appeal of dismissed IPO securities class action](https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/) BioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers. ## Latest BioAge Labs news 1. 2026-01-21 Financings [BioAge sells $115 million of stock at $19.50 after NLRP3 pill cuts CRP 86% in obese patients](https://aibio.space/news/bioage-sells-115-million-stock-19-50-after-nlrp3-pill-cuts-crp-86/) BioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor. ## BioAge Labs at a glance - **Ticker**: BIOA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $318.7 million ### Related companies - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) NASDAQ: JBIO - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) NASDAQ: IAM - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [NANOLOGIX INC](https://aibio.space/companies/nanologix/) OTC: NNLX - [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) NASDAQ: FENC - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) NASDAQ: VYGR - [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE ### Also on NASDAQ - [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) PTCT - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) PTGX - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) PRQR - [InflaRx](https://aibio.space/companies/inflarx-n-v/) IFRX - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) MDCX - [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) APRE ## What BioAge Labs does BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program is BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor. The first therapeutic area for BGE-102 is cardiometabolic disease, with a focus on atherosclerotic cardiovascular disease risk reduction through lowering chronic systemic inflammation measured by high-sensitivity C-reactive protein. BGE-102 was well-tolerated in the single ascending dose and initial multiple ascending dose cohorts, and the company plans a Phase 2a proof-of-concept trial in patients with obesity and elevated hsCRP. The second area is ophthalmology, starting with diabetic macular edema. BioAge is also developing apelin receptor APJ agonists for obesity, and in June 2025 it announced an option agreement with JiKang Therapeutics for a novel APJ agonist antibody. Its platform draws on proprietary longitudinal human datasets built from serial biobanked samples. Its collaborations include Eli Lilly, for platform-derived programs in molecule discovery, and Novartis, for an ongoing target discovery collaboration. | Product or program | What it is | Stage | |---|---|---| | BGE-102 | Oral brain-penetrant NLRP3 inhibitor for cardiometabolic disease and diabetic macular edema | Phase 1 single and initial multiple ascending dose cohorts; Phase 2a planned | | APJ agonists | Apelin receptor agonists for obesity, oral and subcutaneous programs | preclinical | | Platform-derived programs (Eli Lilly collaboration) | Targets from the BioAge platform for cardiometabolic disease | molecule discovery | Summarised from the company's [10-K filed Mar 24, 2026](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/bioa-20251231.htm). ## BioAge Labs annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$9.0 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | [$0](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | | Research and development | [$74.0 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | [$59.0 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | | Net income (loss) | [-$80.6 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | [-$71.1 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | | Cash from operations | [-$81.6 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | [-$51.5 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | | Cash and equivalents | [$188.9 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526335407/) | [$354.3 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | | Short-term investments | [$92.2 million](https://www.sec.gov/Archives/edgar/data/1709941/000119312526335407/) | [$0](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $74.0 million, plus short-term investments of $244.8 million, $318.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioAge Labs Is there a class action against BioAge Labs? Our latest story on this, dated Aug 5, 2026: "BioAge faces Ninth Circuit appeal of dismissed IPO securities class action". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/). When did BioAge Labs go public? Our latest story on this, dated Aug 5, 2026: "BioAge faces Ninth Circuit appeal of dismissed IPO securities class action". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/). Has BioAge Labs raised money recently? Our latest story on this, dated Jan 21, 2026: "BioAge sells $115 million of stock at $19.50 after NLRP3 pill cuts CRP 86% in obese patients". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bioage-sells-115-million-stock-19-50-after-nlrp3-pill-cuts-crp-86/). What is the ticker symbol of BioAge Labs? BioAge Labs, Inc. trades under the ticker BIOA on NASDAQ. Where is BioAge Labs listed? BioAge Labs, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:Y7G; LS:A40D7P; LSX:A40D7P. What is the SEC CIK of BioAge Labs? The SEC Central Index Key (CIK) for BioAge Labs, Inc. is 1709941. Its filings are on SEC EDGAR. How many shares does BioAge Labs have outstanding? 45,896,909 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is BioAge Labs listed under? Our directory records BioAge Labs, Inc. under United States. What does BioAge Labs do? Our directory classifies BioAge Labs, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of BioAge Labs? The ISIN recorded for BioAge Labs, Inc. is US09077V1008. Does aibio.space cover BioAge Labs? aibio.space lists BioAge Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BioAge Labs incorporated? SEC records list its state or country of incorporation as DE. What does BioAge Labs develop? BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program is BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor. What is BGE-102 from BioAge Labs? BGE-102: Oral brain-penetrant NLRP3 inhibitor for cardiometabolic disease and diabetic macular edema Stage: Phase 1 single and initial multiple ascending dose cohorts; Phase 2a planned. What is APJ agonists from BioAge Labs? APJ agonists: Apelin receptor agonists for obesity, oral and subcutaneous programs Stage: preclinical. ## Investor discussion: BioAge Labs Members talk about BioAge Labs (BIOA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioAge Labs, newest first. Each line links the filing it comes from. 1. 2026-03-24 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1709941/000119312526121862/bioa-20260324.htm) 2. 2026-01-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1709941/000119312526016537/d88736d424b5.htm) 3. 2025-10-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1709941/000119312525228414/bioa-20251002.htm) 4. 2025-03-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1709941/000095017025042759/bioa-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BIOA on TradingView](https://www.tradingview.com/symbols/NASDAQ-BIOA/). ## SEC filings and registration - **SEC name**: BioAge Labs, Inc. - **CIK**: 1709941 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BIOA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 5885 HOLLIS STREET, EMERYVILLE, CA, 94608 - **Phone**: 510-806-1445 - **Shares outstanding**: 45,896,909 as of 2026-07-31 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm) filed 2026-10-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1709941/000119312526335407/bioa-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526268518/bioa-20260610.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/bioa-20260508.htm) filed 2026-05-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1709941/000119312526213466/bioa-20260331.htm) filed 2026-05-08 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1709941/000119312526166738/bioa-20260421.htm) filed 2026-04-21 - [10-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/bioa-20251231.htm) filed 2026-03-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001709941), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BioAge Labs, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BIOA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioAge Labs, Inc. - **Ticker**: BIOA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US09077V1008 - **Other listed symbols**: GETTEX:Y7G; LS:A40D7P; LSX:A40D7P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BIOA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bioage-labs/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioAge Labs (BIOA) news: class action, IPO and offering", 2026-10-31, https://aibio.space/companies/bioage-labs/